# Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Study · id `cardio:ct-nct04680442` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04680442](<https://clinicaltrials.gov/study/NCT04680442>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04680442

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

## Technical summary

Registry record NCT04680442. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT04680442, source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)
- Started: 2021-07-01 (actual) (ClinicalTrials.gov record NCT04680442, source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04680442, source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT04680442, source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)
- Countries: Brazil; Canada; Russia (ClinicalTrials.gov record NCT04680442, source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04680442-2025-04-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Acronym: SCHOLAR-2
- Condition: Breast Cancer
- Condition: Heart Failure
- Intervention (Drug): Trastuzumab
- Intervention (Drug): Pertuzumab
- Intervention (Drug): Trastuzumab emtansine
- Lead sponsor: Population Health Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Population Health Research Institute (`cardio:org-population-health-research-institute`)

## Provenance

Content hash: 2d923610d1e284ff8c66fa20d7c83941212f7cd4a315e3559ce6fd234a07dce4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
